UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35
Benzinga Newsdesk 1 month ago
NewsInitiationAnalyst RatingsPrice Target
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.